Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

January 29, 2020January 29, 2020

Bile Acids Control Differentiation, Activity of Immune Cells that Play Key Role in IBD, Mouse Studies Find

News

Bile acids — acidic liquids produced by the liver and gallbladder to help the body digest food fats — promote the differentiation and activity of different types of immune ... Read more

January 22, 2020January 22, 2020

Phase 2 Trial of Oral Treatment for Ulcerative Colitis Expanding to US, Abivax Says

News

The U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for ABX464, Abivax’s treatment candidate for ulcerative colitis (UC), allowing the company to expand its ... Read more

January 6, 2020January 7, 2020

UK Regulatory Agency Approves Launch of Innovation’s Phase 1 Trial of Brilacidin for Ulcerative Colitis

News

The United Kingdom’s Medicines and Healthcare products Regulatory Agency has approved the launch of Innovation Pharmaceuticals’ Phase 1 trial in healthy volunteers to investigate the safety and properties of ... Read more

December 16, 2019December 16, 2019

FDA Approves Avsola, Remicade Biosimilar, to Treat Crohn’s Disease and Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved Amgen’s Avsola (infliximab-axxq) — a biosimilar to Janssen’s Remicade (infliximab) — to treat adults and children with moderate-to-severe Crohn’s disease ... Read more

November 8, 2019November 8, 2019

Endoscopy Given IBD Patients Within 6 Months of Starting Biologic May Limit Complications, Study Says

News

An GI tract examination by endoscopy given within six months of starting treatment with a biologic may lessen the risk of complications in people with inflammatory bowel disease (IBD), a study ... Read more

October 21, 2019October 21, 2019

Pediatric-onset IBD Patients Experience More Severe Disease Than Those Diagnosed as Adults, Population-Based Study Says

News

Patients whose symptoms of inflammatory bowel disease (IBD) first appeared during their childhood usually experience more severe disease compared with those whose symptoms started later in adulthood, a study ... Read more

October 16, 2019October 16, 2019

Caregivers of People Living with IBD Need Better Support, National Survey Finds

News

Results from a national survey highlight the heavy burden inflammatory bowel disease (IBD) places on patients’ family and friends, and the need for new strategies to provide better support ... Read more

September 20, 2019September 20, 2019

Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment

News

Innovation Pharmaceuticals is planning a first clinical trial of an oral formulation of Brilacidin as a treatment for ulcerative colitis (UC), one of the most common types of inflammatory bowel disease (IBD). ... Read more

September 6, 2019September 6, 2019

Stelara Approved to Treat Moderate to Severe Ulcerative Colitis in Europe

News

The European Commission (EC) has approved Stelara (ustekinumab) to treat moderately to severely active ulcerative colitis (UC) in adults who are either not responding to, or are intolerant of, ... Read more

August 12, 2019August 12, 2019

IBD Patients at Higher Risk of Developing Type 2 Diabetes, Study in Denmark Suggests

News

Patients with inflammatory bowel disease (IBD) are at higher risk of developing type 2 diabetes, compared with the general population, according to a study conducted in Denmark. The study, ... Read more